Politicians urge Obama to allow public review of IP provisions in TPP

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Politicians urge Obama to allow public review of IP provisions in TPP

Six members of US Congress have written to US President Barack Obama expressing concern that "secret" negotiations over intellectual property in the Trans Pacific Partnership (TPP) Agreement benefit pharmaceutical companies at the expense of public health.

The six Democrats - Jan Schakowsky (Illonois), Michael Michaud (Maine), Rosa DeLauro (Conneticut), George Miller (California), Barbara Lee (California) and Peter Welch (Vermont) - said the current proposals would have "profound and long-lasting consequences".

In the letter, sent yesterday, the Members urged Obama not to make any final trade agreements "that affect critical health issues" until members of the public and Congress have had the opportunity to review the provisions and provide input.

In particular, they argued that proposed provisions relating to data exclusivity, patent registration and procedure and enforcement would "delay generic competition and increase the price of medicine" and lead to "preventable illnesses and deaths".

"Certainly, trade negotiations conducted behind closed doors are not the place to make changes that would have such profound consequences for patents and veterans, as well as state and federal budgets," they wrote.

Although the TPP negotiations were meant to have been conducted in secret, whistleblowing website WikiLeaks has released several documents which suggest the US is exerting "great pressure" on other nations to adopt stricter IP policies. In the latest release, yesterday, WikiLeaks published two leaked documents that suggest that the US is isolated in its positions on many IP policies.

more from across site and SHARED ros bottom lb

More from across our site

VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Academic Eden Sarid joins us during Pride Month to discuss queer expression and IP law, Patagonia v Pattie Gonia, and how queer and AI-generated creations both pose novelty concerns
Patent attorney Michael Henson joins the firm to lead its freshly launched blockchain and digital assets practice
A dispute over mammogram technology, and a development in the case between GSK and Moderna were also among the top talking points in recent weeks
With rankings for Western Europe set to be published on June 25, we sat down with our research lead to find out what practitioners and law firms can expect
Peter O’Sullivan, a professional services executive, says he is looking forward to helping Pearce IP become the leading life sciences firm in Australia and New Zealand
Matteo Di Lernia, advocate at LCA Studio Legale, unpicks the CJEU’s ruling in M.M. Ristorazione v Villa Ramazzini, including its impact on litigation strategies
Gift this article